Food retailers from supercenter operator Wal-Mart to the four-aisle stores of Aldi are grabbing for bigger shares of the consumer's food dollar with a new round of store expansions in the Indianapolis area.
At least 18 stores are under construction or planned, plus numerous store remodelings, at a construction tab that likely tops $200 million.
The surge in bricks-and-mortar investment is in response to a growing "foodie" culture, in which consumers shop more often, frequent multiple stores and increasingly search out gourmet, organic and other specialty items. At the same time, shoppers want low prices ��and reward stores that offer them ��forcing retailers to keep costs down even as they spend heavily on new stores.
Hot Low Price Stocks To Buy For 2014: Thoratec Corporation(THOR)
Thoratec Corporation engages in the development, manufacture, and marketing of proprietary medical devices used for circulatory support. The company?s primary product lines include ventricular assist devices, such as HeartMate II, an implantable left ventricular assist device consisting of a rotary blood pump to provide intermediate and long-term mechanical circulatory support (MCS); and HeartMate XVE, an implantable and pulsatile left ventricular assist device for intermediate and longer-term MCS. Its ventricular assist devices also comprise Paracorporeal Ventricular Assist Device, an external pulsatile ventricular assist device, which provides left, right, and biventricular MCS approved for bridge-to-transplantation (BTT), including home discharge, and post-cardiotomy myocardial recovery; and Implantable Ventricular Assist Device, an implantable and pulsatile ventricular assist device designed to provide left, right, and biventricular MCS approved for BTT comprising hom e discharge, and post-cardiotomy myocardial recovery. The company also provides CentriMag, an extracorporeal full-flow acute surgical support platform that offers support up to 30 days for cardiac and respiratory failure. In addition, it offers PediMag and PediVAS extracorporeal full-flow acute surgical support platforms designed to provide acute surgical support to pediatric patients. The company sells its products through direct sales force in the United States, as well as through a network of distributors internationally. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.
Advisors' Opinion:- [By Brian Pacampara]
What: Shares of medical device company Thoratec (NASDAQ: THOR ) sank 12% today after its quarterly results missed Wall Street expectations. �
Hot Low Price Stocks To Buy For 2014: RLJ Lodging Trust(RLJ)
RLJ Lodging Trust is an independent equity real estate investment trust. The firm also manages real estate funds. It invests in the real estate markets of the United States. The firm primarily invests in premium-branded, focused service, and compact full-service hotels. RLJ Lodging Trust was launched in 2000 and is domiciled in Bethesda, Maryland.
Advisors' Opinion:- [By Markus Aarnio]
American Hotel Income Properties' competitors include Hospitality Properties Trust (HPT), RLJ Lodging Trust (RLJ), and Hersha Hospitality Trust (HT).
Top 10 Recreation Stocks To Own Right Now: Illumina Inc.(ILMN)
Illumina, Inc. develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include HiSeq 2000, an instrument for high-throughput (up to 200 Gb per run and up to 25 GB per day) sequencing using sequencing-by-synthesis (SBS) technology; Genome Analyzer IIx, an instrument for medium to high-throughput (up to 95 Gb per run) sequencing using SBS technology; Genome Analyzer IIe, an instrument for low to medium throughput (up to 40 Gb per run) sequencing using SBS technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company?s consumables consist of InfiniumHD Whole-Genome BeadChips comprising HumanOmniExpress, HumanOmni1-Quad, Human1M-Duo, and BovineHD, which are multi-sample DNA analysis microarrays; iSelect Custom Genotyping BeadChips that are custome r designable SNP genotyping arrays; GoldenGate Assay Method, a high throughput assay and genotyping system; GoldenGate Universal-32 Sample BeadChip, which are 32 sample GoldenGate genotyping arrays; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200?500 kb insert paired-end reads; VeraCode GoldenGate that are low plex GoldenGate genotyping arrays compatible with the BeadXpress System; Standard Sequencing Kit, reagents used for SBS chemistry on sequencing platforms; and Infinium Assay Kit, reagents used to perform Infinium assays on the iScan platform. It also provides sequencing and genotyping services. The company?s customers include pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as research centers. It sells its products through distributors in North America, Europe, the Asia-Pacific, the Middle East, and South Africa. Illumina was founded in 1998 and is headquartered in San Dieg o, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Illumina (NASDAQ: ILMN ) , a life science diagnostics company, rallied as much as 15% after the company reported better-than-expected first-quarter earnings results.
Hot Low Price Stocks To Buy For 2014: Tribune Co (TRBAA)
Tribune Company, incorporated on March 19, 1968, is a media and entertainment company engaged in newspaper publishing, television and radio broadcasting and entertainment through its subsidiaries. The Company�� operations are divided into two industry segments: publishing and broadcasting and entertainment. In publishing, the Company�� daily newspapers include the Los Angeles Times, Chicago Tribune, The Baltimore Sun, Sun Sentinel (South Florida), Orlando Sentinel, Hartford Courant, The Morning Call and Daily Press. The company�� broadcasting group operates 23 television stations, WGN America on national cable and Chicago�� WGN-AM.
Broadcasting
The Company�� broadcasting owns and operates 23 major-market television stations and reaches more than 80% of United States television households. The group is anchored by WGN America, which can be seen in more than 70 million United States households via cable and satellite services. 13 Tribune stations are affiliates of The CW. Seven are FOX affiliates.
Publishing
The Company�� newspapers include the Los Angeles Times and Chicago Tribune. Tribune Media Services specializes in entertainment listings and syndication, providing news and information for print, broadcast and interactive media.
Tribune Digital
Tribune Digital manages the operations of Tribune�� daily newspapers and their associated Websites, plus all aspects of the Company�� classified advertising operations, as well as Websites for Tribune�� TV stations. Its national classified sites include CareerBuilder.com, Cars.com and Apartments.com.
Advisors' Opinion:- [By John Mitchell]
Gannett (NYSE: GCI ) and the Tribune Co. (NASDAQOTH: TRBAA ) , two companies that publish daily newspapers, have announced combined layoffs of 1,000 positions (not all in the newsroom). News magazines are feeling the same pinch. According to a recent Gallup poll, only 9% of adults get their news from print sources, with news magazines scoring the lowest. The Pew news study as early as 2010 listed online news as the primary source for 39% of adults. �One of Time's biggest competitors, Newsweek, ended its paper publication in early 2013 in favor of an online edition only.
- [By Michael Lewis]
The owner of the Los Angeles Times, and recent bankruptcy court emergent,�Tribune� (NASDAQOTH: TRBAA ) �has made some interesting moves since its downfall in 2008, when the company drowned under the weight of its $13 billion debt load -- a parting gift from a leveraged buyout a year earlier. This week, the story got even more interesting, as management announced that the company would split its profitable operations (TV), and its less appealing businesses (papers), into two separate entities. While more details need to emerge before we can determine whether the company is a worthwhile investment, this unloved company could present an interesting opportunity to sophisticated investors.
- [By Tim Brugger]
Murray McQueen has been named to the newly created position of president, real estate, to oversee Tribune's (NASDAQOTH: TRBAA ) "valuable portfolio of more than seven million square feet of real estate assets," the company announced today. McQueen will take over his new role effective immediately.
Hot Low Price Stocks To Buy For 2014: GreenHaven Continuous Commodity Index Master Fund (GCC)
GreenHaven Continuous Commodity Index Fund (the Fund), incorporated on October 27, 2006, is a statutory trust. The investment objective of the Fund and The GreenHaven Continuous Commodity Index Master Fund (the Master Fund) is to reflect the performance of the Index, over time, less the expenses of the operations of the Fund and the Master Fund. The Master Fund is a wholly owned subsidiary of the Fund and the Managing Owner. CSC Trust Company (the Trustee) is the sole trustee of the Fund and the Master Fund.
The Master Fund issues common units of beneficial interest, or Master Fund Units, which represent units of fractional undivided beneficial interest in and ownership of the Master Fund. The Fund invests substantially all of its assets in the Master Fund in a master-feeder structure. The Fund holds no investment assets other than Master Fund Units.
Advisors' Opinion:- [By Richard Stavros]
GreenHaven Continuous Commodity Index (GCC) is an exchange-traded fund that aims to track the Equal Weight Continuous Commodity Total Return Index (CCI-TR), which provides exposure to diversified commodities. The index is up 4.75% year-to-date, and up 24.63% over the last five years.
Hot Low Price Stocks To Buy For 2014: Anacor Pharmaceuticals Inc. (ANAC)
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company�s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company�s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed the Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Medicis Pharmaceutical Corporation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.
Advisors' Opinion:- [By Lauren Pollock]
Valeant Pharmaceuticals International Inc.(VRX.T) will pay $142.5 million to Anacor Pharmaceuticals Inc.(ANAC) to resolve all outstanding disputes between the two companies. The settlement resolves litigation over alleged breaches of contract involving Valeant units Dow Pharmaceuticals Sciences Inc. and Medicis Pharmaceutical Corp.
- [By Jake L'Ecuyer]
Top losers in the sector included Horizon Pharma (NASDAQ: HZNP), off 9.5 percent, and Anacor Pharmaceuticals (NASDAQ: ANAC), down 8.2 percent.
Top Headline
The Greenbrier Companies (NYSE: GBX) reported a 13% gain in its fiscal second-quarter earnings. Greenbrier's quarterly profit surged to $15.6 million, or $0.50 per share, versus a year-ago profit of $13.8 million, or $0.45 per share. Excluding one-time items, it earned $0.51 per share. Its revenue climbed 88% to $502.2 million. However, analysts were expecting earnings of $0.60 per share on revenue of $508.69 million. - [By Grace L. Williams]
Honorable mentions go out to Coronado Biosciences (CNDO), after its CEO Harlan Weisman and Jay Lobell, a longtime director, joined forces and bought 20,000 shares for $152,100; and to Anacor Pharmaceuticals (ANAC) after CFO Geoffrey Parker bought 33,000 shares for $224,300. InsiderScore noted that Parker�� purchase was his largest to date and called it a ��ompelling positive event.��/p>
Hot Low Price Stocks To Buy For 2014: XOMA Ltd.(XOMA)
XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcet?s uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.
Advisors' Opinion:- [By Keith Speights]
Good omen
Xoma Pharmaceuticals (NASDAQ: XOMA ) reported first-quarter results on Wednesday. The company announced lower revenue compared with the same period last year, but the market didn't care. Shares surged nearly 19% on other news from Xoma.
No comments:
Post a Comment